US 11,939,390 B2
Methods of treating multiple myeloma
Heloise Audat, Paris (FR); Audrey Bonestebe, Paris (FR); Frank Campana Zambrano, Sudbury, MA (US); Sylvain Huille, Paris (FR); Solenn Le-Guennec, Paris (FR); and Lucie Manache-Alberici, Paris (FR)
Assigned to Sanofi-Aventis U.S. LLC, Bridgewater, NJ (US)
Filed by Sanofi-Aventis U.S. LLC, Bridgewater, NJ (US)
Filed on Jan. 28, 2020, as Appl. No. 16/775,025.
Claims priority of provisional application 62/943,716, filed on Dec. 4, 2019.
Claims priority of provisional application 62/931,014, filed on Nov. 5, 2019.
Claims priority of provisional application 62/899,094, filed on Sep. 11, 2019.
Claims priority of provisional application 62/861,954, filed on Jun. 14, 2019.
Claims priority of provisional application 62/847,826, filed on May 14, 2019.
Claims priority of provisional application 62/797,876, filed on Jan. 28, 2019.
Claims priority of application No. 19306554 (EP), filed on Dec. 3, 2019.
Prior Publication US 2020/0239589 A1, Jul. 30, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 31/454 (2006.01); A61K 31/573 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C12Q 1/6869 (2018.01)
CPC C07K 16/2896 (2013.01) [A61K 31/454 (2013.01); A61K 31/573 (2013.01); A61P 35/00 (2018.01); C12Q 1/6869 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)] 19 Claims
 
1. A method of improving renal impairment in an individual in need thereof,
wherein the individual has multiple myeloma, and
wherein the individual has one or more of: chronic obstructive pulmonary disorder (COPD), asthma, and bronchospasms,
comprising administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone,
wherein the anti-CD38 antibody is isatuximab and is administered at a dose of 10 mg/kg, the pomalidomide is administered at a dose of 4 mg, and the dexamethasone is administered at a dose of 40 mg wherein the individual is under 75 years of age, or at a dose of 20 mg wherein the individual is 75 years of age or older, thereby improving renal impairment,
wherein the individual has received at least two prior therapies for multiple myeloma,
wherein at least one of the at least two prior therapies for multiple myeloma was lenalidomide and at least one of the at least two prior therapies was a proteasome inhibitor, and
wherein the individual is more likely to achieve a complete renal response following the treatment, as compared to a treatment comprising the pomalidomide and the dexamethasone without the anti-CD38 antibody.